Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic Spontaneous Urticaria

22 trials tracked for Chronic Spontaneous Urticaria: 14 in phase 3 or 4 and 9 with published results. The most-cited published study has 129 citations.

22Trials tracked
14Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 1 Phase 3 13 Phase 2 7 Phase 1 1
  1. Phase 3 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed · 129 cited
  2. Phase 3 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines Completed · 106 cited
  3. Phase 3 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines Completed · 106 cited
  4. Phase 3 A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Completed · 69 cited
  5. Phase 3 A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Completed · 69 cited
  6. Phase 3 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed · 38 cited
Show 16 more trials
  1. Phase 3 Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria Completed · 29 cited
  2. Phase 3 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) Completed · 24 cited
  3. Phase 3 A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines Completed · 1 cited
  4. Phase 4 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed
  5. Phase 3 A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines Completed
  6. Phase 3 A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. Completed
  7. Phase 3 To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria Completed
  8. Phase 3 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) Completed
  9. Phase 2 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria Completed
  10. Phase 2 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Completed
  11. Phase 2 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Completed
  12. Phase 2 Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) Completed
  13. Phase 2 Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU Completed
  14. Phase 2 This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines Completed
  15. Phase 2 An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU Completed
  16. Phase 1 Mepolizumab for the Treatment of Chronic Spontaneous Urticaria Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FcεRII (CD23) serves a regulatory role in IgE homeostasis and may act as a biomarker
Neurology Sys. Review
FcεRII (CD23) serves a regulatory role in IgE homeostasis and may act as a biomarker CD23 May Offer New Insights for Chronic Skin Conditions
This narrative review synthesizes literature from 1980 to 2024 regarding the role of FcεRII (CD23) in skin diseases including atopic dermati…
New research highlights how the CD23 protein may play a key role in managing IgE levels and inflammation in skin diseases like atopic dermat…
Frontiers Aug 11, 2026
Systematic review links viral infections to persistent and chronic urticaria in children and adults
Allergy & Immunology Meta-analysis
Systematic review links viral infections to persistent and chronic urticaria in children and adults Viral infections may trigger hives that last months or turn chronic in some people
This systematic review of 596 participants examined the association between viral infections and infection-associated urticaria. Findings in…
A review of 596 patients found that viral infections can cause hives lasting months or progressing to a chronic condition in some cases.
Frontiers May 26, 2026
Network meta-analysis of classical TCM formulas as adjuncts to antihistamines for chronic spontaneous urticaria
Drug Pipeline Meta-analysis
Network meta-analysis of classical TCM formulas as adjuncts to antihistamines for chronic spontaneous urticaria Chinese Herbs May Stop Hives From Coming Back
This network meta-analysis of 5,814 patients with chronic spontaneous urticaria synthesized evidence on classical TCM formulas as adjuncts t…
Combining traditional Chinese herbs with standard allergy medicine may help people with stubborn hives feel better sooner and keep the rash …
Frontiers Apr 22, 2026
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients
Pediatrics Cohort
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients This Hives Medicine Might Help Young Children Finally Find Relief
This retrospective case series assessed omalizumab in 13 Chinese children under 12 years with chronic spontaneous urticaria.
A common hives drug shows promise for younger kids who usually have few options.
Frontiers Apr 21, 2026
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
Dermatology Phase III
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria Can a new treatment finally help those suffering from chronic hives?
A Phase 3 trial assesses barzolvolimab's efficacy and safety in CSU patients unresponsive to antihistamines.
Adults with chronic hives who don't get relief from standard antihistamines may find new hope in a new treatment called barzolvolimab being …
CT.gov Mar 28, 2026

Questions about Chronic Spontaneous Urticaria

What are the safety results for barzolvolimab in chronic spontaneous urticaria patients?

Barzolvolimab is generally well tolerated in clinical trials, with hair color change being the most common side effect, though long-term safety data beyond 12 weeks is still missing.

Full answer →